Immunohistochemical analysis of CYP2A13 in various types of human lung cancers

Cancer Science

Volumn 101, Issue 4, 2010, Pages 1024-1028

  Fukami, Tatsuki ^a   Nakajima, Miki ^a   Matsumoto, Isao ^b   Zen, Yoh ^c   Oda, Makoto ^b   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^c KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A; CYTOCHROME P450 2A13; CYTOCHROME P450 2A6; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CYP2A13 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL; SMOKING; SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; ANIMAL; BIOTRANSFORMATION; ENZYMOLOGY; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; RESPIRATORY SYSTEM; SMALL CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CARCINOMA, BRONCHOGENIC; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; RESPIRATORY SYSTEM;

EID: 77957274074     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01482.x     Document Type: Article

References (26)

1. Fernandez-Salguero P, Hoffman SMG, Cholerton S et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995; 57: 651-60.
2. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990; 29: 1322-9.
3. Su T, Bao Z, Zhang QY et al. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 2000; 60: 5074-9.
4. Koskela S, Hakkola J, Hukkanen J et al. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol 1999; 57: 1407-13.
5. Gu J, Su Y, Chen QY et al. Expression and biotransformation enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity. Toxicol Appl Pharmacol 2000; 165: 158-62.
6. Bao Z, He XY, Ding X et al. Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab Dispos 2005; 33: 258-61.
7. Nakajima M, Itoh M, Sakai H et al. CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int J Cancer 2006; 119: 2520-6.
8. Fukami T, Katoh M, Yamazaki H et al. Human cytochrome P450 2A13 efficeintly metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. Chem Res Toxicol 2008; 21: 720-5.
9. Chang JT, Chang H, Chen PH et al. Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. Clin Cancer Res 2007; 13: 38-45.
10. Murray GI, Taylor MC, McFadyen MCE et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997; 57: 3026-31.
11. Spivack SD, Hurteau GJ, Reilly AA et al. CYP1B1 expression in human lung. Drug Metab Dispos 2001; 29: 916-22.
12. Zhu LR, Thomas PE, Lu G et al. CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody. Drug Metab Dispos 2006; 34: 1672-6.
13. *17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 2004; 76: 519-27.
14. Yamanaka H, Nakajima M, Fukami T et al. CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab Dispos 2005; 33: 1811-8.
15. Wu ZL, Sohl CD, Shimada T et al. Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol Pharmacol 2006; 69: 2007-14.
16. 5 in bacterial membranes. Drug Metab Dispos 1999; 27: 999-1004.
17. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriopharge T4. Nature 1970; 227: 680-5.
18. Wong HL, Zhang X, Zhang QY et al. Metabolic activation of the tobacco carcinogen 4-(methylnitrosamino)-(3-pyridyl)-1-butanone by cytochrome P450 2A13 in human fetal nasal microsomes. Chem Res Toxicol 2005; 18: 913-8.
19. Zhang X, D'Agostino J, Wu H et al. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. J Pharmacol Exp Ther 2007; 323: 570-8.
20. Marek CJ, Tucker SJ, Koruth M et al. Expression of CYP2S1 in human hepatic stellate cells. FEBS Lett 2007; 581: 781-6.
21. Wang SY, Hu YL, Wu YL et al. A comparative study of the risk factors for lung cancer in Guangdong, China. Lung Cancer 1996; 14 (Suppl 1): S99-105.
22. Brownson RC, Chang JC, Davis JR. Gender and histologic type variations in smoking-related risk of lung cancer. Epidemiology 1992; 3: 61-4.
23. Morabia A, Wynder EL. Cigarette smoking and lung cancer cell types. Cancer (Phil) 1991; 68: 2074-8.
24. Hoffmann D, Rivenson A, Murphy SE et al. Cigarette smoking and adenocarcinoma of the lung: the relevance of nicotine-derived N-nitrosamines. J Smok Rel Disord 1993; 4: 165-89.
25. Wang H, Tan W, Hao B et al. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 2003; 63: 8057-61.
26. Kiyohara C, Takayama K, Nakanishi Y. CYP2A13, CYP2A6, and the risk of lung adenocarcinoma in a Japanese population. J Health Sci 2005; 51: 658-66.